Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mmr Vaccine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    42 result(s) found for: Mmr Vaccine. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2016-001104-36 Sponsor Protocol Number: IIV-291 Start Date*: 2016-06-01
    Sponsor Name:RIVM
    Full Title: Immunogenicity and safety study of a third measles mumps rubella (MMR-3) vaccine dose in healthy young adults in The Netherlands
    Medical condition: immunological response to an extra mumps immunization (in healthy volunteers)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001901-18 Sponsor Protocol Number: LGS.MMR.01.2016.2022 Start Date*: 2017-02-14
    Sponsor Name:The Danish National University Hospital "Rigshospitalet"
    Full Title: Measles-mumps-rubella vaccine at 6 months of age, immunology, and childhood morbidity in a high-income setting
    Medical condition: Infection with measles, mumps or rubella
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10036654 Prevention LLT
    Population Age: Preterm newborn infants, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-001509-15 Sponsor Protocol Number: 208109/231 Start Date*: 2015-06-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine (Havrix) [720 El.U/0.5 mL dose] admini...
    Medical condition: Active immunization against hepatitis A of healthy children 15 months of age at the time of the first study vaccination.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004905-26 Sponsor Protocol Number: 115649 Start Date*: 2012-10-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Immunogenicity and safety study of GSK Biologicals’ Priorix® vaccine (209762) at an end of shelf-life potency compared to Merck & Co., Inc.’s MMR vaccine when both are given on a 2-dose schedule to...
    Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy children in their second year of life).
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10028257 Mumps PT
    17.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    17.0 10021881 - Infections and infestations 10039252 Rubella PT
    17.0 10021881 - Infections and infestations 10027011 Measles PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-005860-31 Sponsor Protocol Number: 111870 Start Date*: 2015-06-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Immunogenicity of GlaxoSmithKline Biologicals’ MMR vaccine (209762) vs. M-M-R® II, when co-administered with hepatitis A, varicella and pneumococcal conjugate vaccines to children 12-15 months of age
    Medical condition: Diseases caused by measles, mumps, rubella and varicella viruses
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001694-14 Sponsor Protocol Number: CYD08 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-002456-21 Sponsor Protocol Number: 74082 Start Date*: 2020-05-28
    Sponsor Name:Radboudumc
    Full Title: Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine: a possible preventive approach against COVID-19 (BCG-PLUS)
    Medical condition: Trained immunity COVID-19 This study will investigate whether oral bisphosphonate supplementation or the MMR vaccine can be used as immune potentiators when simultaneously administered with BCG, t...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004891-12 Sponsor Protocol Number: 115648 Start Date*: 2012-11-02
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIA, randomized, observer-blind, controlled, multinational consistency study to evaluate the immunogenicity and safety of GSK Biologicals' MMR vaccine (209762) (Priorix®) compared to Merck...
    Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy children in their second year of life).
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10028257 Mumps PT
    18.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    18.0 10021881 - Infections and infestations 10039252 Rubella PT
    18.0 10021881 - Infections and infestations 10027011 Measles PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) FI (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004638-32 Sponsor Protocol Number: 115158 Start Date*: 2015-06-11
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIIA, observer-blind, randomized study to evaluate non-inferiority of a second dose of GSK Biologicals’ measles-mumps-rubella vaccine vs. a second dose of Merck & Co., Inc.’s MMR vaccine wh...
    Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy subjects, 4 to 6 years of age).
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10028257 Mumps PT
    18.0 10022891 - Investigations 10059638 Mumps antibody test PT
    18.0 10021881 - Infections and infestations 10027015 Measles like illness LLT
    18.0 10021881 - Infections and infestations 10039270 Rubella viral infections HLT
    18.0 10021881 - Infections and infestations 10027011 Measles PT
    18.0 100000004858 10027022 Measles-like rash LLT
    18.0 10022891 - Investigations 10039261 Rubella immunity (confirmed) LLT
    18.0 10021881 - Infections and infestations 10028262 Mumps like illness LLT
    18.0 10021881 - Infections and infestations 10039252 Rubella PT
    18.0 10022891 - Investigations 10060066 Measles antibody PT
    18.0 10022891 - Investigations 10039255 Rubella antibodies not present LLT
    18.0 10021881 - Infections and infestations 10028268 Mumps viral infections HLT
    18.0 10022891 - Investigations 10039259 Rubella antibody test PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-001472-38 Sponsor Protocol Number: MET57 Start Date*: 2018-07-10
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Other Pediatric Vaccines in Healthy Toddlers
    Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-005604-15 Sponsor Protocol Number: 115887 Start Date*: 2015-10-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomised, controlled, single-blind study to evaluate the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered according to a 2-d...
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Children, Under 18 Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001538-28 Sponsor Protocol Number: P130930 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10070264 Measles virus test positive LLT
    Population Age: Newborns, Under 18, Adults Gender: Female
    Trial protocol: FR (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005944-22 Sponsor Protocol Number: 106670 Start Date*: 2006-02-21
    Sponsor Name:GlaxoSmithKline GmbH & Co. KG
    Full Title: Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus intramuscular administration of GlaxoSmithKline Biologicals’ combined meas...
    Medical condition: Active immunization of healthy children aged 11 to 21 months against measles, mumps, rebella and varicella diseases
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-006065-14 Sponsor Protocol Number: 105908 Start Date*: 2006-04-04
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline's (GSK) Biologicals' measles-mumps-rubella-varicella candidate vaccine (MeMuRu-OKA) and ...
    Medical condition: Healthy male and female children between 15 months and 6 years of age who previously received an MMR vaccine will receive one dose of MMR + V or MMRV. A second dose of varicella vaccine will be giv...
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005192-24 Sponsor Protocol Number: HAF65 Start Date*: 2015-11-19
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly with TRIMOVAX™ in 12-13 Months old Healthy Hepatitis A Seronegative Turkish Children
    Medical condition: Measles Mumps Rubella Hepatitis A
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-001861-14 Sponsor Protocol Number: UMCUMMR Start Date*: 2008-02-07
    Sponsor Name:University Medical Center Utrecht
    Full Title: Multicenter randomized clinical trial in Patients with Juvenile Idiopathic Athritis: Safety and efficacy of vaccination with live attenuated Measles, Mumps, Rubella vaccine
    Medical condition: Juvenile Idiopathic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003514-91 Sponsor Protocol Number: V59P10 Start Date*: 2014-09-30
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase 3, Randomized, Observer-blind, Controlled, Multi-Center Study to Compare the Safety of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine with that of a Licensed Meningococcal ACWY P...
    Medical condition: Novartis Meningococcal ACWY Conjugate Vaccine is intended for prevention of meningitis and septicemia caused by Neisseria meningitidis A, C, W-135 and Y.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004731-36 Sponsor Protocol Number: MET58 Start Date*: 2018-09-27
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers in...
    Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) FI (Completed) IT (Completed) ES (Completed) PL (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012202-39 Sponsor Protocol Number: 111763 Start Date*: 2010-11-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ dTpa-IPV vaccine (Boostrix Polio) compared with San...
    Medical condition: Booster immunisation against diphtheria, tetanus, pertussis, poliomyelitis, measles, mumps and rubella in healthy preschool children previously vaccinated with 3 doses of DTPa and polio vaccine.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000062-14 Sponsor Protocol Number: MN42988 Start Date*: 2021-10-08
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IV MULTICENTER, OPEN-LABEL STUDY EVALUATING B CELL LEVELS IN INFANTS POTENTIALLY EXPOSED TO OCRELIZUMAB DURING PREGNANCY – THE MINORE STUDY
    Medical condition: Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications]
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10071068 Clinically isolated syndrome PT
    Population Age: In utero, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 06:50:45 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA